相似文献
1
Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.人类免疫缺陷病毒1型蛋白酶和逆转录酶基因中的插入：临床影响和分子机制
Antimicrob Agents Chemother. 2005 Jul;49(7):2575-82. doi: 10.1128/AAC.49.7.2575-2582.2005.
2
Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.高效抗逆转录病毒疗法失败与蛋白酶及1型人类免疫缺陷病毒逆转录酶基因突变
J Infect Dis. 1999 Aug;180(2):568-71. doi: 10.1086/314909.
3
Antiretroviral Resistance Mutations (revised April 2001).抗逆转录病毒耐药性突变（2001年4月修订）
HIV Clin Trials. 2001 Jul-Aug;2(4):346-55. doi: 10.1310/8FXB-B0EK-D525-BVU3.
4
Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.来自配对脑脊液和血浆样本的1型人类免疫缺陷病毒逆转录酶和蛋白酶中的抗逆转录病毒耐药性突变
J Infect Dis. 2000 Feb;181(2):740-5. doi: 10.1086/315249.
5
Current insights into reverse transcriptase inhibitor-associated resistance.逆转录酶抑制剂相关耐药性的当前见解。
Antivir Ther. 2001;6 Suppl 2:11-9.
6
HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.来自阿根廷的垂直感染患者的1型艾滋病毒基因型耐药谱揭示了K103N+L100I和L74V突变之间的关联。
Antivir Ther. 2010;15(4):641-50. doi: 10.3851/IMP1571.
7
A fossil record of zidovudine resistance in transmitted isolates of HIV-1.HIV-1传播株中齐多夫定耐药性的化石记录。
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13485-7. doi: 10.1073/pnas.251559398.
8
Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.西班牙初治和经治患者中耐药突变的流行情况。
Antivir Ther. 1999;4 Suppl 3:57-63.
9
Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.1型人类免疫缺陷病毒O组逆转录酶和蛋白酶中与体内病毒学治疗失败相关的天然残基与抗逆转录病毒药物选择的突变
AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1385-94. doi: 10.1089/08892220050140937.
10
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.2001 年至 2006/2007 年期间，法国新感染抗逆转录病毒的慢性 HIV 感染者中传播耐药突变和非 B 亚型流行率增加。
J Antimicrob Chemother. 2010 Dec;65(12):2620-7. doi: 10.1093/jac/dkq380. Epub 2010 Oct 21.
引用本文的文献
1
HIV Protease Hinge Region Insertions at Codon 38 Affect Enzyme Kinetics, Conformational Stability and Dynamics.HIV 蛋白酶铰链区 38 位密码子的插入影响酶动力学、构象稳定性和动力学。
Protein J. 2023 Oct;42(5):490-501. doi: 10.1007/s10930-023-10132-6. Epub 2023 Jul 8.
2
Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat.使用增强型蛋白酶抑制剂（达芦那韦/利托那韦或达芦那韦/考比司他）进行抗逆转录病毒治疗的管理
Biomedicines. 2021 Mar 18;9(3):313. doi: 10.3390/biomedicines9030313.
3
Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several Retroviruses.插入作为几种逆转录病毒中针对整合酶抑制剂的耐药机制。
Clin Infect Dis. 2019 Sep 27;69(8):1460-1461. doi: 10.1093/cid/ciz136.
4
GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.GS-8374，一种含膦酸酯的 HIV-1 蛋白酶的原型抑制剂，能够有效抑制具有氨基酸插入的蛋白酶突变体。
J Virol. 2014 Mar;88(6):3586-90. doi: 10.1128/JVI.02688-13. Epub 2013 Dec 26.
5
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.核苷逆转录酶抑制剂（NRTI）BMS-986001 对已知 NRTI 耐药突变的体外交叉耐药谱。
Antimicrob Agents Chemother. 2013 Nov;57(11):5500-8. doi: 10.1128/AAC.01195-13. Epub 2013 Aug 26.
6
HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.带有 20 种突变的 HIV-1 蛋白酶通过协调的结构重排表现出对临床抑制剂的极端耐药性。
Biochemistry. 2012 Apr 3;51(13):2819-28. doi: 10.1021/bi2018317. Epub 2012 Mar 20.
7
Current and Novel Inhibitors of HIV Protease.当前和新型 HIV 蛋白酶抑制剂。
Viruses. 2009 Dec;1(3):1209-39. doi: 10.3390/v1031209. Epub 2009 Dec 11.
8
The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.逆转录酶核苷酸切除在HIV耐药性中的作用
Viruses. 2010 Jan 28;2(2):372-394. doi: 10.3390/v2020372.
9
The remarkable frequency of human immunodeficiency virus type 1 genetic recombination.1型人类免疫缺陷病毒基因重组的显著频率。
Microbiol Mol Biol Rev. 2009 Sep;73(3):451-80, Table of Contents. doi: 10.1128/MMBR.00012-09.
10
Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.对蛋白酶抑制剂地瑞那韦耐药的人类免疫缺陷病毒临床分离株的分子特征分析
J Virol. 2009 Sep;83(17):8810-8. doi: 10.1128/JVI.00451-09. Epub 2009 Jun 17.
本文引用的文献
1
New two-amino acid insertion near codon 70 of the HIV type 1 protease gene.
AIDS Res Hum Retroviruses. 2005 Apr;21(4):311-3. doi: 10.1089/aid.2005.21.311.
2
3
Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.一种在逆转录酶中有8个氨基酸插入的1型人类免疫缺陷病毒变体，其多核苷耐药性增加且复制能力下降。
J Virol. 2005 Mar;79(6):3536-43. doi: 10.1128/JVI.79.6.3536-3543.2005.
4
Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication.人类免疫缺陷病毒1型逆转录酶中的Gln145Met/Leu变化赋予对核苷和非核苷类似物的抗性并损害病毒复制。
Antimicrob Agents Chemother. 2004 Dec;48(12):4611-7. doi: 10.1128/AAC.48.12.4611-4617.2004.
5
Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.在Gag裂解位点附近的氨基酸插入可恢复对蛋白酶抑制剂耐药的1型人类免疫缺陷病毒变体原本受损的复制能力。
J Virol. 2004 Nov;78(21):12030-40. doi: 10.1128/JVI.78.21.12030-12040.2004.
6
Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.1型人类免疫缺陷病毒逆转录酶中Delta67复合突变对核苷类似物切除的影响
J Virol. 2004 Sep;78(18):9987-97. doi: 10.1128/JVI.78.18.9987-9997.2004.
7
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.一种萘啶羧酰胺为HIV-1整合酶机制相同的抑制剂之间的不一致耐药性提供了证据。
Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11233-8. doi: 10.1073/pnas.0402357101. Epub 2004 Jul 26.
8
Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.在逆转录酶的指状亚结构域带有二肽插入以及密码子67和215处发生突变的多核苷类似物耐药HIV-1毒株的相对复制适应性
Virology. 2004 Aug 15;326(1):103-12. doi: 10.1016/j.virol.2004.06.006.
9
Resistance to enfuvirtide, the first HIV fusion inhibitor.对恩夫韦肽（首个HIV融合抑制剂）的耐药性。
J Antimicrob Chemother. 2004 Aug;54(2):333-40. doi: 10.1093/jac/dkh330. Epub 2004 Jul 1.
10
Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).HIV-1逆转录酶引发的引物解封及对核苷类逆转录酶抑制剂（NRTIs）的耐药性。
Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705. doi: 10.1016/j.biocel.2004.02.028.
Zotero 插件